← All trials
NCT04856644
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 1, 2021
- Primary completion
- Dec 31, 2023
- Completion date
- Dec 31, 2024
- First posted
- Apr 23, 2021
- Last posted
- Apr 23, 2021
- Enrollment
- 366
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Kaohsiung Medical UniversityLead sponsor
- Chang Gung UniversityCollaborator
- Taipei Veteran General hospitalCollaborator
- Government of TaiwanCollaborator
- National Taiwan UniversityCollaborator
- Kaohsiung Medical UniversityReponsible party - principal investigator
- Kaohsiung Medical UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.